Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Medigene AG
Medigene AG
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
MediGene and Johns Hopkins University sign AAVLP pact
Will examine product candidates for the prevention of HPV-associated diseases
Research & Development
MediGene to cut workforce by half
Management aims to strengthen pipeline through strategic deal
Research & Development
MediGene divests Oncolytic Herpes Simplex Viruses programme to Catherex
MediGene to receive 40% stake in Catherex
Pharmaceutical
MediGene and Teva to commercialise Veregen
German biotech company MediGene has signed an agreement with Teva Pharmaceutical Industries for the supply and commercialisation of a genital warts treatment in Israel.
Subscribe now